Dania Therapeutics ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2022–2025
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Balance — aktiver | ||||
| Likvide beholdninger | 170.000 | 12.888.821 | 5.112.499 | 2.740.271 |
| Omsætningsaktiver i alt | 2.990.000 | 15.063.137 | 7.136.312 | 3.502.316 |
| Anlægsaktiver i alt | — | — | — | — |
| Aktiver i alt | 2.990.000 | 15.063.137 | 7.136.312 | 3.502.316 |
| Balance — passiver | ||||
| Kortfristede gældsforpligtelser | 64.000 | 679.307 | 755.344 | 824.935 |
| Langfristede gældsforpligtelser | 100.000 | 15.610.714 | 16.754.300 | 18.090.467 |
| Gældsforpligtelser i alt | 164.000 | 16.290.021 | 17.509.644 | 18.915.402 |
| Selskabskapital | 55.000 | 59.301 | 59.711 | 59.711 |
| Overført resultat | -9.741.000 | -18.463.235 | -10.433.043 | -15.472.797 |
| Årets resultat | -9.741.000 | -8.721.963 | -9.556.855 | -5.039.754 |
| Egenkapital i alt | 2.826.000 | -1.226.884 | -10.373.332 | -15.413.086 |
| Resultatopgørelse | ||||
| Omsætning | 0 | 0 | 0 | 0 |
| Resultat af primær drift | -12.859.000 | -10.431.440 | -10.316.654 | -4.390.139 |
| Resultat før skat | -12.561.000 | -10.722.332 | -11.453.754 | -5.761.969 |
| Årets resultat | -9.741.000 | -8.721.963 | -9.556.855 | -5.039.754 |
| Personaleomkostninger | — | 1.240.000 | 1.480.000 | 1.000.000 |
| Af- og nedskrivninger | — | — | — | — |
| Andre nøgletal | ||||
| Ansatte | — | 1 | 1 | 1 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Description of key activities of the companyThe company is engaged in research and development within the field of biotechnology, with a strategic focus on the development of novel medicinal products for the treatment of cancer. Additional activities supporting this objective include preclinical studies, formulation development, and other advancement aimed at enhancing therapeutic delivery and efficacy.
Significant changes in the company's activities and financial mattersThere have been no material changes to the company's operations or financial position during the reporting period. Research and development activities have progressed steadily towards the company’s core projects. Loss from ordinary activities after tax totals DKK -5.040 thousand against DKK -9.557 thousand last year. Management considers the financial performance and scientific progress to be in line with expectations for a company focused on pharmaceutical discovery and development. Looking ahead, the company anticipates that the coming year will provide the opportunity to demonstrate the efficacy of its proprietary compounds through in relevant mice models.
Uddrag af ledelsesberetningen i den seneste årsrapport.